Based on these studies, it has been suggested that the ratio between FC and total cholesterol (TC) is a primary regulator of the APP processing, and that ACAT may be considered as a drug target for therapeutic intervention against certain form(s) of AD [10]. This evidence concerns the gene ACAT1 and Alzheimer disease.